Prognostic Value of Myeloperoxidase in Patients with Chest Pain
New England Journal of Medicine2003Vol. 349(17), pp. 1595–1604
Citations Over TimeTop 1% of 2003 papers
Marie‐Luise Brennan, Marc S. Penn, Frederick Van Lente, Vijay Nambi, Mehdi H. Shishehbor, Ronnier J. Aviles, Marlene Goormastic, Michael Pepoy, Ellen McErlean, Eric J. Topol, Steven E. Nissen, Stanley L. Hazen
Abstract
A single initial measurement of plasma myeloperoxidase independently predicts the early risk of myocardial infarction, as well as the risk of major adverse cardiac events in the ensuing 30-day and 6-month periods. Myeloperoxidase levels, in contrast to troponin T, creatine kinase MB isoform, and C-reactive protein levels, identified patients at risk for cardiac events in the absence of myocardial necrosis, highlighting its potential usefulness for risk stratification among patients who present with chest pain.
Related Papers
- → Risk stratifying acute coronary syndromes: Gradient of risk and benefit(1999)28 cited
- Risk stratifying the acute coronary syndrome patient: a focus on treatable risk.(2007)
- → Stress Testing and Troponin in Unstable Coronary Syndromes: The STATUS Trial?Clinical Outcomes and Resource Use(2006)
- The substitution of troponin in bullfrog and chicken myofibrils by rabbit skeletal troponin, troponin-T and troponin-T1.(1994)